Bortezomib-induced Histiocytoid Sweet Syndrome.
- Author:
Young Jun OH
1
;
Bark Lynn LEW
;
Woo Young SIM
Author Information
1. Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea. bellotte@hanmail.net
- Publication Type:Case Report
- Keywords:
Bortezomib;
Sweet syndrome
- MeSH:
Aged;
Bortezomib;
Fever;
Humans;
Incidence;
Multiple Myeloma;
Neck;
Neutrophils;
Skin;
Standard of Care;
Sweet Syndrome*;
Upper Extremity
- From:Korean Journal of Dermatology
2016;54(9):739-743
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sweet syndrome is an acute febrile neutrophilic dermatosis predominantly characterized by fever, an elevated neutrophil count, and erythematous skin lesions comprising plaques and nodules that mainly appear on the upper extremities, face, and neck. The incidence of Sweet syndrome in the general population is unknown because of limited reports on this condition. Bortezomib, an antineoplastic agent that is the standard of care for multiple myeloma, has been reported to be associated with Sweet syndrome. We describe the case of a 66-year-old man who developed bortezomib-induced histiocytoid Sweet syndrome during treatment for multiple myeloma.
